Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum

Xeroderma pigmentosum (XP) is a genetic disease in which DNA repair mechanisms are impaired. Cisplatin (CDDP) exerts cytotoxic effects by forming mainly intrastrand DNA cross-links, and sensitivity to CDDP depends on the DNA repair system. Several in vitro studies have suggested that treatment with...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2017/04/15, Vol.56(8), pp.979-982
Main Authors: Sumiyoshi, Makoto, Soda, Hiroshi, Sadanaga, Noriaki, Taniguchi, Hirokazu, Ikeda, Takaya, Maruta, Hiroshi, Dotsu, Yosuke, Ogawara, Daiki, Fukuda, Yuichi, Mukae, Hiroshi
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents - adverse effects
Antitumor agents
Cancer
Case Report
CDDP
Chemotherapy
Cisplatin
Cisplatin - adverse effects
Cytotoxicity
Deoxyribonucleic acid
DNA
DNA repair
DNA repair system
Fatal Outcome
Female
Humans
Internal medicine
Male
Medical personnel
multiple organ failure
Multiple Organ Failure - chemically induced
Neoplasms - drug therapy
Patients
Xeroderma Pigmentosum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Xeroderma pigmentosum (XP) is a genetic disease in which DNA repair mechanisms are impaired. Cisplatin (CDDP) exerts cytotoxic effects by forming mainly intrastrand DNA cross-links, and sensitivity to CDDP depends on the DNA repair system. Several in vitro studies have suggested that treatment with CDDP may cause enhanced adverse events as well as anti-tumor activity in cancer patients with XP. This article is the first to describe two cancer patients with XP showing severe adverse events following CDDP-based chemotherapy. Physicians should pay attention when administering CDDP in cancer patients with XP.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.56.7866